Sizavaleucel

司佐沃仑赛

Report date: 2023/01/12 15:52:32

Base Information

Drug NameSizavaleucel

Drug Alias Nameallogeneic HLA-matched living donor hematopoetic stem cell therapyMDR-101

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy +[4]

Mechanisms of ActionCell replacementsImmunomodulatorsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsRejection of renal transplantation

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesMedeor Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesMedeor Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsRejection of renal transplantation

Inactive IndicationsN/A

Other Information

ATC CodeN/A